Bio Plus Co Ltd

Capital Structure and Liquidity Bio Plus Co Ltd has a total equity of KRW 174,842.79 billion and total liabilities of KRW 110,197.22 billion, resulting in a debt-to-equity ratio of 0.34, which is relatively low. However, the company's liquidity position is assessed as medium, with a current ratio of 0.84, indicating that its current assets are less than its current liabilities. The company has KRW 21,074.15 billion in cash and equivalents, but this is offset by KRW 60,061.01 billion in long-term debt, resulting in a net cash position that is negative after subtracting total debt. ### Profitability and Returns The company's profitability is reflected in its return on equity (ROE) of 8.58% and return on assets (ROA) of 5.26%. These figures suggest that the company is generating a reasonable return on its equity and assets, though the ROE is below the typical benchmark for high-growth pharmaceutical firms. The net income of KRW 15,001.44 billion and operating income of KRW 14,909.37 billion indicate strong operational performance, but the free cash flow is negative at KRW -23,868.34 billion, which may signal reinvestment in the business or capital expenditures. ### Segments and Geographic Exposure The company's revenue is concentrated in its core pharmaceutical business, with no disclosed geographic breakdown. This lack of geographic diversification may expose the company to regional economic or regulatory risks. The company's primary markets are likely within South Korea, given the absence of international revenue segments in the provided data. ### Growth Trajectory The company's revenue for the latest period is KRW 90,896.01 billion, and while there is no explicit growth rate provided, the negative free cash flow and significant capital expenditures suggest that the company is investing heavily in its operations. The analyst estimates indicate a mean recommendation of 1.00 (strong buy), with one strong-buy rating and no buy, hold, sell, or strong-sell ratings, suggesting strong investor confidence in the company's future performance. ### Risk Factors The company faces medium liquidity risk due to its current ratio of 0.84 and a negative net cash position after accounting for long-term debt. The dilution risk is assessed as low, with no significant dilution potential in the basic shares outstanding. The company's capital expenditures are substantial, which may impact its free cash flow and financial flexibility. ### Recent Events There are no specific recent events or filings mentioned in the provided data. However, the company's strong analyst ratings and high net income suggest that it has been performing well in the recent period.